<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827969</url>
  </required_header>
  <id_info>
    <org_study_id>IB2009-58</org_study_id>
    <nct_id>NCT01827969</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy</brief_title>
  <acronym>USF</acronym>
  <official_title>Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment consists of tumor ablation by Ablathermy Focused Ultrasound (USF), guided by&#xD;
      MRI, performed under local anesthesia and sedation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment consists of tumor ablation by USF, guided by MRI, performed under local&#xD;
      anesthesia and sedation. Patients will be operated (mastectomy) from 48 hours after ablation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties&#xD;
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effectiveness of ablathermy</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the effectiveness of ablathermy focused ultrasound breast tumors on histological criteria in terms of destruction of the tumor mass by coagulation necrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Assessment of apoptotic phenomena in the margins of lesions treated</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of apoptotic phenomena in the margins of lesions treated&#xD;
Know the immediate complications focused ultrasound&#xD;
Assess the pain experienced by patients during the procedure performed under sedation.&#xD;
Check the real-time processing by mapping temperature measured by MRI and correlate these mappings to the histological findings</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Tumor</condition>
  <arm_group>
    <arm_group_label>ablathermy focused ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ablathermy focused ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ablathermy focused ultrasound</intervention_name>
    <description>ablathermy focused ultrasound</description>
    <arm_group_label>ablathermy focused ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Invasive Breast Carcinoma with histologically confirmed hormone receptor analysis, the&#xD;
             grade of the tumor, the expression of Her-2.&#xD;
&#xD;
          -  Lesion classified T1-T2-T3 unifocal or multifocal with or without associated&#xD;
             microcalcifications&#xD;
&#xD;
          -  Lesion recognizable and identifiable in MRI&#xD;
&#xD;
          -  Indication of mastectomy with or without axillary&#xD;
&#xD;
          -  Lesion located more than 10 mm from the skin, the nipple and pectoralis major&#xD;
&#xD;
          -  No cons-indication to MRI (pacemaker)&#xD;
&#xD;
          -  Women whose age is ≥ 18 years&#xD;
&#xD;
          -  If premenopausal patient: patient contraceptives&#xD;
&#xD;
          -  Patient has signed informed consent&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor-TD T4B classified or non-palpable lesion&#xD;
&#xD;
          -  If age &lt;70 years: no indication of adjuvant chemotherapy and neoadjuvant&#xD;
&#xD;
          -  MRI lesions have not been identified, located within 10 mm of the skin and pectoral&#xD;
             muscle, greater than 25 mm diameter&#xD;
&#xD;
          -  Inability to hold still in the prone position, arms extended, for 30 minutes&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Patient deprived of liberty and major subject of a measure of legal protection or&#xD;
             unable to consent&#xD;
&#xD;
          -  Patient participating in another interventional clinical trial within 30 days prior to&#xD;
             baseline and during the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PALUSSIERE Jean, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Women</keyword>
  <keyword>breast tumor</keyword>
  <keyword>planned mastectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

